Fortress Biotech (FBIO) Reports Q2 Loss of $0.73/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Fortress Biotech (FBIO) PT Raised to $13 at Roth/MKM
August 14, 2024 5:06 AM EDTRoth/MKM analyst Jason Whittes raised the price target on Fortress Biotech (NASDAQ: FBIO) to $13.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "FBIO reported 2Q24 revenues down 14.4% to $14.9 million vs. consensus of $14.8 million and our estimate of $14.0 million. EPS was ($0.73) vs.... More
